Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf107 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Vincenza Conteduca und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, 71122 Fogg…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Circulating Tumor DNA, Biomarkers, Tumor, Bone Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) acts as an early biomarker of the efficacy of androgen receptor signaling inhibitor (ARSI) therapy. In this study, we aimed to reveal if ctDNA can supplement imaging to better predict metastasis burden and radiographic progression disease (PD) in metastatic castration-resistant prostate cancer (mCRPC).
Methods
Targeted next-generation sequencing was performed to assess ctDNA fraction. Radiographic evidence was documented by conventional imaging according to Prostate Cancer Working Group 3 criteria.
Results
We prospectively collected plasma samples from 112 mCRPC with bone (n = 77), lymph nodal (n = 31), and visceral (n = 4) metastases. Only bone metastatic patterns were significantly associated with median ctDNA at baseline, during treatment and at PD (P <.0001). At first radiographic restaging, 24 (31.2%) men with a progressive worsening of bone disease had early ctDNA rise with a % ctDNA variation of 150.6% (interquartile range [IQR] = 104.9-210.7] compared with 11.1% (IQR = 0-36.6), P <.0001, in men with no change in bone disease. Univariate analysis showed that early ctDNA rise was significantly associated with progression free/overall survival (PFS/OS). In multivariable analysis including ctDNA change from baseline to 3-month treatment, variation of bone metastatic patterns (from oligometastatic to polymetastatic and/or to widespread disease), presence of visceral metastasis, age, PSA, performance status and prior docetaxel therapy, the transition from low- to high-ctDNA within 3 months of starting ARSI therapy was a significant predictor of OS (HR = 2.50, 90% CI, 1.06-5.88, P =.035) and persistent high level of ctDNA was a predictor of PFS (HR = 2.53, 95% CI, 1.10-5.81, P =.028). Metastatic involvement demonstrated that the transition from bone polymetastatic to widespread disease and the presence of visceral metastases were both associated with worse OS (HR = 2.43, 95% CI, 1.10-5.35, P =.028, and HR = 3.40, 95% CI, 1.50-7.66, P =.003, respectively). Prior therapy with docetaxel represented an independent predictor of both PFS and OS (HR = 2.47, 95% CI, 1.40-4.35, P =.002, and HR = 1.78, 95% CI, 1.00-3.15, P =.049, respectively).
Conclusions
Early ctDNA variation might reflect changes in metastatic burden and, likely, in bone metastatic patterns on ARSI therapy allowing to track pattern of disease progression and to predict outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, 71122 Foggia, Italy.
- Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014 Meldola, Italy.
- Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014 Meldola, Italy.
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014 Meldola, Italy.
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014 Meldola, Italy.
- Nuclear Medicine Operative Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014 Meldola, Italy.
ORCID-Profile: Vincenza Conteduca, Alessandra Virga
Förderung
- Italian Ministry of Health
Zitieren
APA
Conteduca, V., Scarpi, E., Rossi, A., Ferroni, F., Gurioli, G., Bleve, S., Gianni, C., Schepisi, G., Brighi, N., Lolli, C., Cursano, M. C., Virga, A., Casadei, C., Altavilla, A., Farolfi, A., Ulivi, P., Barone, D., Matteucci, F., & De Giorgi, U. (2025). Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyaf107
Vancouver
Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, et al. Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyaf107
BibTeX
@article{Conteduca2025,
author = {Conteduca, Vincenza and Scarpi, Emanuela and Rossi, Alice and Ferroni, Fabio and Gurioli, Giorgia and Bleve, Sara and Gianni, Caterina and Schepisi, Giuseppe and Brighi, Nicole and Lolli, Cristian and Cursano, Maria Concetta and Virga, Alessandra and Casadei, Chiara and Altavilla, Amelia and Farolfi, Alberto and Ulivi, Paola and Barone, Domenico and Matteucci, Federica and De Giorgi, Ugo},
title = {Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf107}
}
EUVIMED